Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Theravance Biopharma Clear all
Completed Phase 2 Interventional Results available

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02040792
View directory record Official record
Conditions
COPD
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

NCT01040637
View directory record Official record
Conditions
Healthy, Opioid-induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Pasadena, California • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

NCT00442832
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
TD-1792, Vancomycin
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02518139
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208, Tiotropium
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

NCT01718938
View directory record Official record
Conditions
Gastroparesis
Interventions
velusetrag dose 1, velusetrag dose 2, velusetrag dose 3, placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Tucson, Arizona • Los Angeles, California • Ventura, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

NCT02578082
View directory record Official record
Conditions
Renal Impairment
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TD-9855 to Treat Fibromyalgia

NCT01693692
View directory record Official record
Conditions
Fibromyalgia
Interventions
TD-9855 Group 1, TD-9855 Group 2, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
34
States / cities
Huntsville, Alabama • Goodyear, Arizona • El Cajon, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

NCT04688632
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions
Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

NCT01568411
View directory record Official record
Conditions
Healthy
Interventions
TD-1211, TD-1211+ itraconazole
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1607 MAD Study in Healthy Subjects

NCT01949103
View directory record Official record
Conditions
Infections, Bacterial Infections
Interventions
TD-1607, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

NCT02459080
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-9855 Mass Balance Study

NCT01924143
View directory record Official record
Conditions
ADHD, Fibromyalgia
Interventions
TD-9855
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

NCT02657122
View directory record Official record
Conditions
Healthy
Interventions
TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD, Placebo for MAD
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT03408470
View directory record Official record
Conditions
Intestinal Disorders, Bowel Diseases, Inflammatory
Interventions
TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

NCT00391820
View directory record Official record
Conditions
Chronic Constipation
Interventions
TD-5108
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years to 64 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

NCT02512510
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of TD-1473 in Crohn's Disease

NCT03635112
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, TD-1473
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

NCT02709928
View directory record Official record
Conditions
Healthy Adults, Elderly Subjects
Interventions
TD-0714, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

NCT01655771
View directory record Official record
Conditions
Constipation
Interventions
TD-1211 Dose 1, TD-1211 Dose 2
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 10:06 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions
Ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
26
States / cities
Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

NCT01459926
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Foley, Alabama
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

NCT03095456
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Interventions
Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin, Placebo for Spiriva Handihaler®
Drug · Combination Product
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 10:06 PM EDT